MK-677 (Ibutamoren)

Quick Facts

Introduction

MK-677, also known as ibutamoren, is an orally active growth-hormone secretagogue that activates the same receptor as the hormone ghrelin. It occupies a distinctive position in growth-hormone research: although its mechanism places it firmly in the ghrelin-mimetic family alongside peptides such as Ipamorelin and GHRP-2, MK-677 is itself not a peptide — it is a non-peptide small molecule designed to be taken by mouth.

This oral, non-peptide character is the central reason MK-677 is studied so widely. The injectable peptide secretagogues are limited by short half-lives and the need for parenteral administration, whereas MK-677 was engineered to produce sustained, once-daily stimulation of the GH/IGF-1 axis from an oral molecule. It is examined in the same conceptual conversation as the GHRH analogues CJC-1295 and Sermorelin, which act on a different receptor.

This profile covers what MK-677 is, its molecular characteristics, its GHS-receptor mechanism, the growth-hormone and body-composition research it appears in, and how it compares with related secretagogues. Related compounds are catalogued in the peptide database, and the broader class is summarized in the research library.

What is MK-677?

MK-677 is a non-peptide growth-hormone secretagogue — a synthetic small molecule (a spiropiperidine derivative) developed to mimic the action of ghrelin at the pituitary while remaining orally bioavailable and metabolically stable. Unlike the peptide GHRPs, which must be reconstituted and injected, MK-677 was specifically designed to survive oral administration and to act over a full day from a single exposure.

Functionally it is grouped with the ghrelin-mimetic secretagogues because it activates the same growth-hormone secretagogue receptor (GHS-R1a) as ghrelin and the GHRPs. Chemically, however, it is unrelated to peptides — it has no amino-acid sequence, and its handling and solubility behave like those of a small-molecule research chemical rather than a lyophilized peptide.

Because MK-677 works upstream of growth hormone — prompting the pituitary to release its own stored hormone rather than supplying exogenous GH — the secretion it elicits remains pulsatile and subject to feedback. Its defining practical feature is duration: a single exposure is associated with elevations in growth hormone and IGF-1 that persist over roughly 24 hours, a marked contrast with the brief pulses of the injectable GHRPs.

Molecular and structural characteristics

MK-677 is a spiropiperidine-based small molecule with the molecular formula C₂₇H₃₆N₄O₅S (free base) and a molecular weight of roughly 528.66 g/mol; it is frequently supplied as the more stable mesylate salt. Having no peptide backbone, it is not subject to the peptidase degradation that limits the injectable GHRPs — a structural fact that underlies both its oral activity and its long duration.

Its small-molecule nature also changes how it is handled in the laboratory. Where peptide secretagogues are lyophilized powders reconstituted in sterile or bacteriostatic water, MK-677 is poorly water-soluble and behaves like a typical research chemical, dissolving more readily in organic or acidic vehicles. This is an important practical distinction from the rest of the secretagogue family.

Mechanism of action

MK-677 acts as an agonist at the growth-hormone secretagogue receptor (GHS-R1a), a G-protein-coupled receptor expressed on pituitary somatotrophs and in the hypothalamus. Receptor activation engages the Gq/phospholipase-C pathway, raising intracellular calcium and stimulating the release of stored growth hormone — the same fundamental mechanism used by ghrelin and the peptide GHRPs.

What differs is the kinetics. Because MK-677 is orally available and resistant to enzymatic breakdown, it sustains GHS-receptor stimulation across the day, producing durable elevations in growth hormone and IGF-1 while preserving the underlying pulsatility of the axis. Researchers describe it as amplifying the existing signal rather than replacing it, so feedback from IGF-1 and somatostatin continues to operate.

As a ghrelin-receptor agonist, MK-677 also engages the appetite and energy-balance functions of the GHS system, with a reported orexigenic (appetite-stimulating) effect. And because its receptor is distinct from the GHRH receptor, it is studied for complementarity with GHRH analogues such as CJC-1295, echoing the GHRP-plus-GHRH theme common across secretagogue research.

• GHS-R1a (ghrelin-receptor) agonism on pituitary somatotrophs.
• Gq/phospholipase-C signaling and intracellular calcium rise.
• Sustained, pulsatility-preserving growth-hormone release.
• Durable downstream elevation of IGF-1.
• Appetite stimulation via the ghrelin system.

Growth-hormone axis research

The central research context for MK-677 is the GH/IGF-1 axis. In study populations, oral MK-677 has been associated with increases in growth-hormone secretion and sustained elevations in IGF-1, and — unusually for a secretagogue — it has been examined in longer-duration clinical research rather than only in short provocative tests. This durability is the property that most distinguishes it from the injectable GHRPs.

Because it can be studied over extended periods, MK-677 has been examined in research on age-related decline in GH output and in contexts where preserving lean mass is of interest. It sits in the same conceptual family as the selective peptide Ipamorelin and the potent GHRP-2, and is contrasted with the GHRH analogues Sermorelin and Tesamorelin.

Body composition and metabolic research

Sustained IGF-1 elevation is the reason MK-677 is studied for body-composition endpoints. Research in study populations has examined associations with increases in fat-free (lean) mass, reflecting the anabolic signaling of the GH/IGF-1 axis. Because the compound also engages the ghrelin appetite system, increased food intake is a commonly reported accompaniment in research settings.

Metabolic considerations are also part of the MK-677 literature. Sustained growth-hormone elevation can influence insulin sensitivity and glucose handling, and fluid retention has been reported, so researchers track these endpoints when characterizing the compound. These observations underscore that durable GHS-receptor activation is mechanistically different from the brief pulses of the injectable peptides — a key reason MK-677 is studied as its own distinct case within the secretagogue family.

Comparison: MK-677 vs Ipamorelin vs GHRP-2

MK-677 is most often compared with the peptide ghrelin-mimetics. Ipamorelin is a selective injectable pentapeptide reported to spare cortisol and prolactin; GHRP-2 is a potent injectable hexapeptide. All three activate the GHS receptor, but MK-677 is distinguished by being an orally active, long-acting small molecule rather than a short-acting injectable peptide.

Because its receptor is complementary to the GHRH receptor, MK-677 is also studied conceptually alongside GHRH analogues such as CJC-1295. Full entries for each compound are in the peptide database.

Half-life and pharmacokinetic considerations

MK-677's defining pharmacokinetic feature is its long duration of action from an oral molecule. A single exposure is associated with elevations in growth hormone and IGF-1 that persist over roughly 24 hours, which is why it has been studied on a once-daily basis — a sharp contrast with the minutes-long half-lives of the injectable GHRPs.

This durability is a direct consequence of its non-peptide structure: with no peptide bonds to cleave, it resists the rapid enzymatic degradation that limits the peptide secretagogues. The trade-off researchers consider is that continuous GHS-receptor stimulation, unlike brief pulses, raises questions about steady-state IGF-1 levels and metabolic effects that must be tracked over time.

Preparation and handling considerations

Unlike the peptide secretagogues, MK-677 is a small molecule and is not reconstituted from a lyophilized powder in the peptide sense. It is poorly water-soluble, so research preparations typically use organic or acidic vehicles rather than plain sterile water, and it is most often supplied as the more stable mesylate salt.

Because its handling differs from peptides, the standard peptide reconstitution calculator and reconstitution guide apply only loosely; researchers select a vehicle and working concentration suited to a small molecule. Solutions should be clear, and any preparation showing precipitation or discoloration is discarded.

• Treat as a small molecule, not a lyophilized peptide.
• Use a vehicle appropriate to a poorly water-soluble compound.
• Confirm the solution is clear and free of precipitate before use.
• Protect from light, moisture, and excess warmth.

Storage considerations

As a small-molecule research chemical, MK-677 is generally stored dry, away from light and moisture, either at room temperature or refrigerated depending on the supplier's specification — it does not require the frozen storage typical of lyophilized peptides. Any prepared solution is kept refrigerated and used within a limited window.

Research limitations

MK-677 is a research compound. Although it has a longer-duration clinical research record than most secretagogues, sustained GHS-receptor activation raises distinct considerations: reported effects on appetite, fluid retention, and insulin sensitivity must be weighed, and the consequences of continuous (rather than pulsatile) IGF-1 elevation remain an active research question. Reported effects are dose-, duration-, and population-dependent. It is described here strictly for research reference.

• Sustained, non-pulsatile stimulation differs mechanistically from brief peptide pulses.
• Appetite increase, fluid retention, and altered insulin sensitivity are reported.
• Reported effects are dose-, duration-, and population-dependent.
• It is not an approved therapy and is described solely for research reference.

Frequently Asked Questions

Related Research Profiles

References

1. Nass R, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med. 2008;149(9):601-611.Source
2. Chapman IM, et al. Oral administration of growth hormone (GH) releasing peptide-mimetic MK-677 increases markers of GH secretion in healthy older adults. J Clin Endocrinol Metab. 1996;81(12):4249-4257.Source
3. Smith RG. Development of growth hormone secretagogues. Endocrine Reviews. 2005.